Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study by Guler, Sabina A et al.








Pulmonary function and radiological features 4 months after COVID-19:
first results from the national prospective observational Swiss COVID-19
lung study
Guler, Sabina A ; Ebner, Lukas ; Aubry-Beigelman, Catherine ; Bridevaux, Pierre-Olivier ; Brutsche,
Martin ; Clarenbach, Christian ; Garzoni, Christian ; Geiser, Thomas K ; Lenoir, Alexandra ;
Mancinetti, Marco ; Naccini, Bruno ; Ott, Sebastian R ; Piquilloud, Lise ; Prella, Maura ; Que, Yok-Ai ;
Soccal, Paula M ; von Garnier, Christophe ; Funke-Chambour, Manuela
Abstract: Background The infectious coronavirus disease 2019 (COVID-19) pandemic is an ongoing global
healthcare challenge. Up to one-third of hospitalised patients develop severe pulmonary complications and
acute respiratory distress syndrome. Pulmonary outcomes following COVID-19 are unknown. Methods
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COVID-19. We report on initial follow-up 4 months after mild/moderate or severe/critical COVID-19
according to the World Health Organization severity classification. Results 113 COVID-19 survivors were
included (mild/moderate n=47, severe/critical n=66). We confirmed several comorbidities as risk factors
for severe/critical disease. Severe/critical disease was associated with impaired pulmonary function, i.e.
diffusing capacity of the lung for carbon monoxide (DLCO) % predicted, reduced 6-min walk distance
(6MWD) and exercise-induced oxygen desaturation. After adjustment for potential confounding by age,
sex and body mass index (BMI), patients after severe/critical COVID-19 had a DLCO 20.9% pred (95%
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associated with previous severe/critical disease when age, sex, BMI, 6MWD and minimal peripheral
oxygen saturation at exercise were included in the multivariable model (adjusted odds ratio per 10%
predicted 0.59, 95% CI 0. 37–0.87; p=0.01). Mosaic hypoattenuation on chest computed tomography
at follow-up was significantly associated with previous severe/critical COVID-19 including adjustment
for age and sex (adjusted OR 11.7, 95% CI 1.7–239; p=0.03). Conclusions 4 months after severe acute
respiratory syndrome coronavirus 2 infection, severe/critical COVID-19 was associated with significant
functional and radiological abnormalities, potentially due to small-airway and lung parenchymal disease.
A systematic follow-up for survivors needs to be evaluated to optimise care for patients recovering from
COVID-19.
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ABSTRACT
Background: The infectious coronavirus disease 2019 (COVID-19) pandemic is an ongoing global
healthcare challenge. Up to one-third of hospitalised patients develop severe pulmonary complications and
acute respiratory distress syndrome. Pulmonary outcomes following COVID-19 are unknown.
Methods: The Swiss COVID-19 lung study is a multicentre prospective cohort investigating pulmonary
sequelae of COVID-19. We report on initial follow-up 4 months after mild/moderate or severe/critical
COVID-19 according to the World Health Organization severity classification.
Results: 113 COVID-19 survivors were included (mild/moderate n=47, severe/critical n=66). We
confirmed several comorbidities as risk factors for severe/critical disease. Severe/critical disease was
associated with impaired pulmonary function, i.e. diffusing capacity of the lung for carbon monoxide
(DLCO) % predicted, reduced 6-min walk distance (6MWD) and exercise-induced oxygen desaturation.
After adjustment for potential confounding by age, sex and body mass index (BMI), patients after severe/
critical COVID-19 had a DLCO 20.9% pred (95% CI 12.4–29.4% pred, p=0.01) lower at follow-up. DLCO %
pred was the strongest independent factor associated with previous severe/critical disease when age, sex,
BMI, 6MWD and minimal peripheral oxygen saturation at exercise were included in the multivariable
model (adjusted odds ratio per 10% predicted 0.59, 95% CI 0. 37–0.87; p=0.01). Mosaic hypoattenuation
on chest computed tomography at follow-up was significantly associated with previous severe/critical
COVID-19 including adjustment for age and sex (adjusted OR 11.7, 95% CI 1.7–239; p=0.03).
Conclusions: 4 months after severe acute respiratory syndrome coronavirus 2 infection, severe/critical
COVID-19 was associated with significant functional and radiological abnormalities, potentially due to
small-airway and lung parenchymal disease. A systematic follow-up for survivors needs to be evaluated to
optimise care for patients recovering from COVID-19.
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Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the coronavirus that leads to
coronavirus disease 2019 (COVID-19) and the current pandemic is the most critical ongoing global
healthcare problem. To date, >1.4 million people have died of COVID-19 [1]. In Switzerland, as of
November 25, 2020, a total of 309469 patients had been diagnosed with COVID-19 and 4030 patients had
died [2].
COVID-19 is a heterogeneous disease with most patients experiencing mild illness and spontaneous
recoveries, but a relevant subgroup of individuals require hospitalisation for pneumonia and other
complications. In the initial reports from Wuhan, China, up to one-third of patients developed severe
pneumonia with acute respiratory distress syndrome (ARDS) [3]. While we have already discovered much
about the pathogenesis and treatment of the acute SARS-CoV-2 disease, intermediate and long-term
outcomes are still unknown, particularly in survivors of severe disease courses.
Previous coronavirus infections include severe acute respiratory syndrome (SARS) and Middle East
respiratory syndrome (MERS). Similar to COVID-19, SARS and MERS typically begin with an acute
illness from which most patients recover after 2 weeks. However, up to one-third of SARS patients
developed severe pulmonary complications and ARDS [4]. A subgroup of SARS survivors developed
persistent lung parenchymal abnormalities, including pulmonary fibrosis [5, 6]. The appearance of
pulmonary fibrosis correlated with the severity and duration of the acute illness [7, 8], and radiological
features of fibrosis persisted in ∼30% of patients after 3 and 6 months [9, 10]. Older age and male sex
were identified as risk factors for poor outcomes and development of lung fibrosis [9, 11].
With the anticipation of potential long-term sequelae after COVID-19, follow-up strategies have been
proposed by several groups from the United States, United Kingdom, China and India [12–15].
Switzerland was one of the first European countries to be affected by COVID-19, with an increasing
number of confirmed cases from February 25, 2020 onwards [2]. A nationwide lockdown was initiated on
March 16, 2020 to prevent further spreading. 6 months later, we are facing not only challenges in acute
COVID-19 patient care, but also in the follow-up and management of COVID-19 survivors presenting
with sequelae of the disease.
We initiated the multicentre Swiss national COVID-19 lung study group to assess pulmonary sequelae of
COVID-19. In this first analysis of our prospective cohort we report on chronic pulmonary sequelae of
patients who had experienced mild to moderate (mild/moderate) and severe to critical (severe/critical)
COVID-19, with the goal to improve the current understanding of the heterogeneous COVID-19
trajectories.
Methods
Study setting, patients and clinical measurements
This national, multicentre, prospective observational cohort study includes adults who survived acute
COVID-19 and presented for clinical follow-up after either mild/moderate or severe/critical COVID-19.
Contributing centres for the Swiss COVID-19 lung study are the University Hospital Bern (Inselspital and
Tiefenauspital), Lausanne University Hospital, University Hospital Geneva, University Hospital Zurich,
Kantonspital St. Gallen, Kantonspital Freiburg, Hospital of Sion, Hospital of Basel (Claraspital), and
Hospital of Tessin (Clinica Luganese Moncucco). All patients provided written informed consent before
inclusion. Ethics approval was obtained prior to start of the study on May 1, 2020 (KEK 2020–00799).
Affiliations: 1Dept of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern,
Switzerland. 2Dept of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital,
University of Bern, Bern, Switzerland. 3Radiodiagnostic and Interventional Radiology, CHUV-University
Hospital, Lausanne, Switzerland. 4Service de Pneumologie, Hôpital du Valais, Sion, Switzerland. 5Lung Center,
Kantonsspital St. Gallen, St. Gallen, Switzerland. 6Dept of Pneumology, University Hospital Zurich, Zurich,
Switzerland. 7Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano,
Switzerland. 8Dept of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
9Dept for BioMedical Research, University of Bern, Bern, Switzerland. 10Division of Pulmonary Medicine,
Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland. 11Dept of Internal
Medicine, University and Hospital of Fribourg, Fribourg, Switzerland. 12Dept of Pulmonary Medicine, Clinica
Luganese Moncucco, Lugano, Switzerland. 13Dept of Pulmonary Medicine, St. Claraspital AG, Basel,
Switzerland. 14Adult Intensive Care Unit, University Hospital and University of Lausanne, Lausanne,
Switzerland. 15Dept of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern,
Switzerland. 16Division of Pulmonary Medicine, Geneva University Hospitals, Geneva, Switzerland.
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Baseline information, e.g. symptoms at initial presentation, was retrieved from medical records. Pulmonary
functional tests, measurement of diffusing capacity of the lung for carbon monoxide (DLCO) and 6-min
walk tests (6MWT) were performed using established protocols [16–19]. Respiratory muscle strength was
estimated by measurement of maximum static inspiratory pressure and maximum static expiratory
pressure at the mouth [20]. Chest computed tomography (CT) scans were performed in clinically
symptomatic patients.
Patients were stratified into the following two groups according to four severity grades described by the
World Health Organization: 1) mild disease, or moderate disease with clinical signs of pneumonia and
peripheral oxygen saturation (SpO2) ⩾90% (mild/moderate); 2) severe disease with pneumonia and SpO2
<90%, respiratory rate >30 breaths·min−1 or critical disease, i.e. ARDS, sepsis, septic shock and multiorgan
failure (severe/critical) [21].
Chest CT acquisition
Standard chest CT scans were acquired according to the local protocols in participating centres. 52
follow-up chest CT scans from the 113 included patients were available. All chest CT scans were
reconstructed with ∼1 mm slice thickness. Application of iodine contrast agents was only performed if
pulmonary embolism was suspected and/or in case of clinical deterioration. Multiplane reconstructions
were performed in axial, coronal and sagittal planes as required. All images were reconstructed with lung
and soft tissue kernels and stored in the local picture archiving and communication system (PACS).
Image analysis
All available CT scans were collected from Bern and Lausanne and de-identified in the local image archive
system (PACS Carestream Health, Rochester, NY, USA for Lausanne; Sectra PACS, IDS7, Linköping,
Sweden for Bern). Two subspecialised chest radiologists from two tertiary-care centres performed a
consensus readout, blinded to the clinical status of the patients. For the reading process, the radiologists
reviewed the cases online via screen sharing (Cisco Webex, Milpitas, CA, USA), as the current pandemic
regulations restrict physical meetings. The readers assessed the presence of the following chest CT patterns:
consolidation, ground-glass opacities (focal, multifocal, diffuse), mosaic attenuation pattern
(hypoattenuating areas, hyperattenuating areas), perilobular consolidation (organising pneumonia-like
pattern), reticulations, architectural distortion, honeycombing, traction bronchiectasis, pneumatoceles,
curvilinear lines, nodules, pleural thickening or pleural effusion, mucus plugging, vascular abnormalities
and additional findings were annotated separately. Additionally, pattern distribution was recorded (upper
lobe, middle lobe/lingual, lower lobe). A semiquantitative estimation of the disease extent was performed,
based on the system proposed by FRANCONE et al. [22]. The CT score is derived from extent of lobar
involvement based on a five-point scale (0: 0%, 1: <5%, 2: 5–25%, 3: 26–50%, 4: 51–75%, 5: >75%; range
0–5; global score 0–25).
Statistical analysis
Descriptive statistics are reported as mean±SD or median (interquartile range (IQR)). Differences between
mild/moderate and severe/critical COVID-19 groups were analysed for statistical significance by
Chi-squared or Fisher’s exact test for categorical variables and by two-sample t-test or Wilcoxon rank-sum
test for continuous variables as applicable. The associations of demographic factors, pulmonary and
physical function tests, and radiological signs with the COVID-19 severity groups were estimated using
linear or logistic regression models where applicable. Models were adjusted for potential confounders with
either conceptual importance (age, sex) or a statistically significant relationship to COVID-19 severity
(p<0.1). Model fit was examined using the area under the receiver operating characteristic curve (AUC).
95% confidence intervals for AUC were calculated from bootstrap resampling with 2000 repetitions. The
final models were selected based on overall AUC. A two-sided p<0.05 was considered for all comparisons.
Data were analysed using R (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics and symptoms
Collaborating centres included 113 patients (n=66 after severe/critical and n=47 after mild/moderate
COVID-19) from May 1, 2020 until September 15, 2020 (figure 1). Median (IQR) time from initial
symptoms to the follow-up visit was 128 (108–144) days.
Patients who survived severe/critical COVID-19 were older than patients followed-up after mild/moderate
disease (mean±SD age 60.3±12 versus 52.9±11 years, with equal sex distribution) (table 1). Smoking history
in mild/moderate and severe/critical COVID-19 patients was not significantly different. However, mean±SD
body mass index (BMI) was significantly higher in patients with severe/critical disease than in those with
mild/moderate disease (29.8±5.7 versus 25.5±4.7 kg·m−2, p=0.02). Initial comorbidities in both groups are
https://doi.org/10.1183/13993003.03690-2020 3
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listed in table 1. At follow-up, patients in both COVID-19 severity groups did not indicate relevant cough
(median (IQR) cough visual analogue scale 0 (0–2)). However, patients reported persistent exertional
dyspnoea in both groups (median (IQR) modified Medical Research Council score 1 (0–1)) at follow-up.
A sensitivity analysis excluding patients with previously diagnosed chronic lung diseases was performed to
estimate if the observed differenced in follow-up pulmonary function were mainly driven by pre-existing
lung diseases. Supplementary table S1 demonstrates the mainly unchanged findings in this subgroup.
Pulmonary function, physical performance and oxygenation
Overall, average pulmonary function was normal in patients after mild/moderate COVID-19. Patients after
severe/critical COVID-19 had generally lower lung volumes that were still within the normal range,
whereas average measures of diffusion capacity (DLCO), physical performance and oxygenation were
reduced. Specifically, total lung capacity (TLC), forced vital capacity (FVC), forced expiratory volume in
1 s (FEV1) and DLCO were significantly lower in patients after severe/critical COVID-19 compared to
patients after mild/moderate disease. Furthermore, COVID-19 patients with mild/moderate disease course
had a lower ratio of FEV1/FVC than those with severe/critical illness (table 1). Patients with severe/critical
disease had impaired and significantly lower DLCO compared to patients with mild/moderate disease
(mean±SD 73.2±18.4% pred versus 95.3±20.3% pred, p=0.003). 6-min walk distance (6MWD) was 120 m
lower in the severe/critical disease group, with an average SpO2 decrease of 5.6±3.8% in the severe/critical
group compared to 2.6±3.1% in the mild/moderate disease group (p=0.02). Similarly, 4 months after
COVID-19, former severe/critical patients had lower arterial oxygen tension (PaO2) compared to former
mild/moderate patients (PaO2 79±12.2 versus 87.5±9 mmHg, p=0.0002) (table 1). Respiratory muscle
strength did not differ in both groups.
Within the subgroup of patients who needed mechanical ventilation (39 patients with severe/critical
disease) several measures of pulmonary function at follow-up were negatively correlated with the duration
of mechanical ventilation during acute COVID-19 (supplementary table S2). Specifically, DLCO and TLC
showed a moderately strong negative correlation with duration of ventilation (r=−0.43, p=0.008 and r=−0.42,
p=0.01, respectively).
Clinical associations with a severe/critical disease course
Unadjusted analysis showed patients after severe/critical COVID-19 being 7.4 (95% CI 3–11.7) years older
(p=0.002) and having a 4.4 (95% CI 2.3–6.4) kg·m−2 higher BMI (p<0.001) than patients after mild/
moderate disease. FVC % predicted was 9% (95% CI 1.5–16.4%) lower and TLC % predicted was 16%
113 survivors of SARS-CoV-2 infection
Severe to critical disease
n=66
Missing data
  Smoking status 34
  BMI 4
  Comorbidities 33
  Initial symptoms 39
  Symptoms at follow-up 34
  Pulmonary function tests 3
  DLCO 6
  Arterial blood draw 7
  6MWT 9
  Respiratory muscle strength 20
Missing data
  Smoking status 4
  BMI 1
  Comorbidities 7
  Initial symptoms 7
  Symptoms at follow-up 3
  Pulmonary function tests 2
  DLCO 5
  Arterial blood draw 14
  6MWT 9
  Respiratory muscle strength 34
Missing data
  BMI 3
  Pulmonary function tests 3
  DLCO 3
  Arterial blood draw 3
  6MWT 2
Missing data
  BMI 0
  Pulmonary function tests 0
  DLCO 0
  Arterial blood draw 0
  6MWT 0
Mild to moderate disease
n=47
Severe to critical disease
n=44
Mild to moderate disease
n=8
Available clinical and pulmonary function data
Available chest CT scans (n=52)
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of the study. SARS-CoV-2: severe acute respiratory
syndrome coronavirus 2; BMI: body mass index; DLCO: diffusing capacity of the lung for carbon monoxide; 6MWT: 6-min walk test; CT: computed
tomography.
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(95% CI 8.3–23.6%) lower after severe/critical COVID-19 than after mild/moderate COVID-19. After
adjustment for age, sex and BMI, TLC remained significantly lower in the severe/critical disease group
(14.6% pred, 95% CI 6.3–22.8% pred; p<0.001), whereas FVC lost statistical significance (5.6% pred, 95%
CI −2.6–13.8% pred; p=0.18). DLCO was significantly higher after mild/moderate COVID-19 on
unadjusted analysis (22.1% pred, 95% CI 14.4–29.8% pred; p=0.001), and after adjustment for the
aforementioned confounders (20.9% pred, 95% CI 12.4–29.4% pred; p=0.01).
Similarly, survivors of severe/critical COVID-19 had a markedly lower 6MWD on unadjusted (120 m, 95%
CI 80–160 m; p=0.001) and adjusted analyses (86 m, 95% CI 45–127 m; p=0.001). After adjustment for
age, sex and BMI, minimal SpO2 on 6MWD was 2.2% (95% CI 0.4–4.0%, p=0.01) and PaO2 was 5 mmHg
(95% CI 0.3–10.2 mmHg) lower (p=0.06) after severe/critical disease.
Figure 2 shows the association of follow-up clinical variables with initial severe/critical and mild/moderate
COVID-19. Table 2 illustrates the final multivariable model including clinical and functional variables
TABLE 1 Baseline characteristics and follow-up findings in patients with severe/critical and
mild /moderate coronavirus disease 2019
Severe/critical disease Mild/moderate disease p-value#
Patients n 66 47
Baseline characteristics
Male/female n/n 40/26 27/20 0.89
Age years 60.3±12.0 52.9±10.9 <0.001
Ever-smokers¶ % 56 37 0.16
BMI kg·m−2 29.8±5.7 25.5±4.7 0.02
D-dimer+ µg·L−1 1011 (366–1989) 387 (1–658) 0.26
Mechanical ventilation§ % 71
Duration of mechanical ventilation§ days 11.9 (9.5–18)
Comorbidities %
Interstitial lung disease 6 3 0.58
COPD 12 3 0.18
Asthma 9 19 0.32
Arterial hypertension 55 8 0.003
Diabetes 35 0 0.04
GORD 10 9 1.00
Sleep apnoea 16 3 0.09
Chronic heart failure 10 9 1.00
Chronic renal failure 19 0 0.009
Cancer 6 5 1.00
Depression or anxiety 12 7 0.66
Pulmonary function at follow-upƒ
FEV1/FVC % 94.7±13.7 84.2±14.3 <0.001
TLC L 5.22±1.5 6.5±1.6 0.050
TLC % pred 86.0±20.0 102.0±19.3 0.047
FVC L 3.28±1.01 4.12±1.2 <0.001
FVC % pred 86.6±20.1 95.6±17.9 0.02
FEV1 L 2.64±0.8 3.34±1.1 <0.001
FEV1 % pred 89.4±20.7 94.0±15.6 0.19
DLCO % pred 73.2±18.4 95.3±20.6 0.003
PImax kPa 10.3±8.8 8.1±2.6 0.14
PEmax kPa 8.7±3.3 10.3±4.1 0.20
Oxygenation at follow-upƒ
PaO2 mmHg 79.0±12.2 87.5±9.0 0.0002
6MWD m 456±105 576±78 0.001
O2 nadir on 6MWT 90±4.5 93±3.1 0.001
O2 desaturation on 6MWT 5.6±3.8 2.6±3.1 0.02
Data are presented as mean±SD or median (interquartile range), unless otherwise stated. BMI: body mass
index; GORD: gastro-oesophageal reflux disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; TLC: total lung capacity; DLCO: diffusing capacity of the lung for carbon monoxide; PImax: maximal
inspiratory pressure; PEmax: maximal expiratory pressure; PaO2: arterial oxygen tension; 6MWD: 6-min walk
distance; 6MWT: 6-min walk test. #: p-values from two-sample t-tests, Wilcoxon rank sum test,
Chi-squared test or Fisher’s exact test; ¶: n=38 missing; +: n=59 missing; §: n=11 missing; ƒ: n=72.
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statistically and conceptually associated with a severe/critical course of COVID-19 in our cohort. High
DLCO % predicted at follow-up was the factor with the strongest independent association with a more
favourable previous course of disease (p=0.01). A good model fit was demonstrated by the overall AUC of
0.95 (95% CI 0.88–1.00).
Radiological features
In our cohort, typical radiological follow-up sequelae of COVID-19 included uni- or multi-lobular
hypoattenuated areas without or with bulging of the lobular margins, ground-glass opacities with a mosaic
attenuation pattern, linear/curvilinear densities, reticulations, honeycombing, traction bronchiectasis with
Male
Age per year
BMI per 1 kg·m–2
TLC per  L
TLC per 10% pred
FVC per  L





6MWD per 10 m
SpO2
 min per 1%
SpO2



























Mild/moderate COVID-19 Severe/critical COVID-19
0.3 0.5 1.0 2.0
FIGURE 2 Variables associated with past coronavirus disease 2019 (COVID-19) severity. Association of demographic and functional parameters
with mild/moderate and severe/critical COVID-19. Odds ratios and corresponding 95% confidence intervals from unadjusted analysis and
individual multivariable models for each parameter adjusting for confounding by age and sex. BMI: body mass index; TLC: total lung capacity;
FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; FEV1: forced expiratory volume in 1 s; PaO2: arterial oxygen
tension; 6MWD: 6-min walk distance; SpO2: peripheral oxygen saturation.
TABLE 2 Complete clinical multivariable model for severe/critical disease
OR (95% CI) p-value
DLCO per 10% pred 0.59 (0.37–0.87) 0.01
Age per year 0.98 (0.92–1.05) 0.62
Male 1.98 (0.50–8.56) 0.34
BMI per 1 kg·m−2 1.19 (1.03–1.41) 0.02
6MWD per 10 m 0.88 (0.67–0.95) 0.01
Minimum SpO2 per 1% 0.80 (0.44–0.95) 0.07
Effect estimates indicate the associations of the variables with severe/critical disease in the context of the
complete multivariable model, e.g. for every 10-m increase in 6-min walk distance (6MWD), the odds for
severe/critical disease decreases by 12% adjusting for age, sex, body mass index (BMI), diffusing capacity
of the lung for carbon monoxide (DLCO) and minimal oxygen saturation on 6-min walk test (SpO2). The
overall area under the receiver operating curve of the multivariable model including DLCO, age, sex, BMI,
6MWD and minimal SpO2 was 0.95 (95% CI 0.88–1.00).
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architectural distortion in various locations, as well as pneumatoceles (figure 3). Extensive pulmonary
fibrosis was rarely observed (supplementary figure S1).
Radiological features that were significantly more prevalent after severe/critical than after mild/moderate
COVID-19 included mosaic attenuation pattern with hypoattenuated areas (66% versus 13%, p=0.007),
and reticulations (59% versus 13%, p=0.02) and architectural distortion (52% versus 13%, p=0.055) were
marginally more frequent in severe/critical disease (supplementary table S2).
Our patients with a mosaic attenuation pattern with hypoattenuation areas on chest CT scan were more
than 13 times more likely to have suffered a severe/critical disease course in our study (table 3). This
association remained statistically significant with accounting for potential confounding by age and sex (OR
13, 95% CI 1.7–239 p=0.03). Similarly, reticulations increased the odds of past severe/critical COVID-19
10-fold (95% CI 1.6–198, p=0.04) (table 3).
Discussion
To our knowledge, this is the first European study reporting on respiratory follow-up outcomes after
SARS-CoV-2 infection. After an average observation time of 4 months, our cohort reveals impairments in
pulmonary function and physical performance that were more pronounced in patients with previously
a) b)
c) d)
FIGURE 3 Characteristic radiological changes of a patient with severe sequelae 3 months after coronavirus
disease 2019 (COVID-19) pneumonia. Extensive involvement of both lungs is present in a patient 3 months
after severe COVID-19 pneumonia. Diffuse mosaic attenuation pattern in all lung lobes seen on a) axial
1-mm-thick computed tomography (CT) scan and b) 10-mm-thick minimum intensity projection (mIP) slices,
c) 1-mm-thick CT and d) 10-mm-thick mIP sagittal reformats in lung windowing. This combines classical
features of lung fibrosis with architectural distortion, reticulations, honeycombing (arrowhead in a) and
traction bronchiectasis (straight arrows in a−d), as well as sharply demarcated areas of low attenuation in
both lungs (circles in a−d). Clusters of contiguous hypoattenuating lobules and traction bronchiectasis are
better visualised on mIP images with narrow window settings (b and d). Note the bulging of the interlobular
septae (b and d, curved arrows) as well as the subpleural pneumatocele in c and d.
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severe/critical COVID-19 courses, compared to those with mild/moderate illness. Specifically, DLCO %
predicted at 4 months was the most important independent correlate of a more severe initial disease.
Furthermore, in the subcohort of patients with available chest CT scan, we identified a mosaic attenuation
pattern with hypoattenuated areas of various size limited by geographic margins with bulging of secondary
pulmonary lobules, as well as reticulations as distinct radiological features after severe/critical COVID-19.
Information on risk factors for the development of COVID-19 pneumonia and a severe disease course is
increasing, and our study supports many of the findings from previous reports [23–25]. In our cohort, we
confirm that age and age-associated comorbidities significantly contribute to the inter-individual
heterogeneity in the severity of acute COVID-19 [24]. For example, with obesity emerging as a risk factor
for severe COVID-19 and mortality [26–28], findings from the Swiss COVID-19 lung cohort confirm the
importance of this modifiable risk factor.
COVID-19 primarily affects the lung and airways and may lead to respiratory failure [25]. 5-year survivors
of ARDS were found to be functionally impaired with a median 6MWD 76% of predicted [29]. Similarly,
a meta-analysis on long-term outcomes after SARS and MERS identified a reduced 6MWD and DLCO
compared to healthy individuals [30]. A 3-month follow-up study of a Wuhan cohort (mostly mild
pneumonia) demonstrated reduced pulmonary function in 14 out of 55 cases, including nine out of 55
cases with reduced DLCO [31]. In our study, reduced DLCO, decreased 6MWD and desaturation during
6MWT were associated with the severely impaired COVID-19 phenotype, and importantly this
relationship was not confounded by age, sex or BMI.
The prevalence and extent of pulmonary function and physical impairment after different clinical courses
of COVID-19 are still uncertain. In our cohort we demonstrate lower lung volumes (TLC, FVC and FEV1)
in patients after severe/critical COVID-19; the higher FEV1/FVC ratio in the severe/critical subgroup
suggests a tendency toward a restrictive physiology, and the lack of difference in respiratory muscle
strength suggests a lung parenchymal issue rather than a respiratory muscle issue. Furthermore, we
demonstrate a negative correlation between the duration of mechanical ventilation during the acute disease
and pulmonary function at 4-month follow-up. This might be due to a prolonged impairment after very
severe COVID-19 or related to more severe disease course in susceptible patients. Alternatively, ventilator
induced lung-injury is a well-described challenge post-ARDS, which can impact on pulmonary function
after recovery from the acute illness [29].
On chest CT scans, acute COVID-19 typically presents with progressive ground-glass opacities, alveolar
consolidations with a common subpleural and basal location, rounded lesions, crazy-paving pattern, linear
densities, parenchymal bands and architectural distortion perhaps representing organising pneumonia
and/or fibrotic changes [32]. This presents as an overall radiological picture that is distinct from other
viral infections, such as influenza [33, 34]. Similar to the clinical evolution, the trajectory of radiological
patterns is reported to be heterogeneous. After a mean observation time of 10 days, lung parenchymal
abnormalities seem to have improved in most cases, while some patients persistently show mild signs of
pulmonary fibrosis [35]. At short-term follow-up, the most frequent radiological abnormalities included
ground-glass opacities, consolidation and parenchymal bands [36]. Reports on medium- or long-term
development of radiological abnormalities are currently very limited.
4 months after the initial diagnosis the predominant finding in our severe/critical subcohort was a mosaic
attenuation pattern, characterised by abnormally hypodense areas corresponding to one or several
contiguous secondary pulmonary lobules alternating with normal or abnormally hyperdense areas (i.e.
ground-glass attenuation), as well as more frequent reticulations. In most cases, there was a sharp
demarcation and delineation of the margins of the involved secondary pulmonary lobules, with sometimes
hyperdense bands silhouetting the abnormal lobules. The combination of mosaic attenuation pattern and
TABLE 3 Unadjusted and adjusted association of radiological features with previous severe/
critical coronavirus disease 2019
Unadjusted Adjusted for age and sex
OR (95% CI) p-value# OR (95% CI) p-value#
Hypoattenuation 13.5 (2.1–265) 0.02 11.7 (1.7–239) 0.03
Reticulations 10.1 (1.6–198) 0.04 8.73 (1.3–174) 0.06
Odds ratios indicate the associations of the radiological variables at follow-up with severe/critical disease,
e.g. the odds of severe/critical disease is 11.7 times higher for a patient with than for a patient without
hypoattenuation, adjusting for age and sex. #: p-value for the radiological sign.
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impaired DLCO can either be attributed to abnormalities in the distal airways such as constrictive
bronchiolitis with air trapping and secondary reflex vasoconstriction or a primary pulmonary vascular
disease that may induce secondary airway disease. Both mechanisms can cause ventilation/perfusion
mismatch contributing to the reduced physical performance and hypoxaemia that we observed in our
severe/critical subcohort. Endothelial injury and alveolar capillary microthrombosis have been discussed as
underlying mechanisms of pulmonary vascular disease [37]. In addition, airway disease and air trapping
have been described after adult ARDS in the setting of influenza, MERS and SARS [6, 38, 39]. Overall,
observations from previous studies combined with the high prevalence of the mosaic attenuation pattern
specifically in our severe/critical COVID-19 subcohort suggest that this pattern is an important late feature
of severe COVID-19. Signs of fibrosis that we observed in our cohort (reticulations, bronchiectasis and
honeycombing) are frequently encountered in survivors of ARDS. While initial observations reported
fibrosis after COVID-19-associated ARDS [38], mosaic attenuation and air trapping have not been
described after COVID-19 before. We recently reported that radiological mosaic attenuation and air
trapping might indicate small airway disease [40]. This finding has been reported previously after
coronavirus infection and virus-associated ARDS [6, 38, 39]. The radiological and functional abnormalities
observed in our study might represent residual damage after ARDS in general, after ventilator-induced
lung injury, or specifically after SARS-CoV-2 infection. Potential development of progressive interstitial
lung disease after COVID-19 might be attributed to stimulation of autoimmune pathways triggered by
SARS-CoV-2 or progression from pre-existing interstitial lung abnormalities to clinically significant
interstitial lung disease.
Prolonged functional impairment with slow recovery over several years after ARDS is not uncommon [29];
however, potential long-term consequences specifically after COVID-19 still need to be investigated in
future observational studies.
The design of our study does not allow any inference of the prevalence of severe/impaired and mild/
moderate COVID-19, as patients who died were not included, and we did not include asymptomatic
patients for follow-up. Initial pulmonary function tests and imaging were not available; consequently,
patients who experienced severe/critical disease might have had a predisposing undiagnosed lung disease
and poorer pulmonary function at follow-up. Patients were questioned thoroughly for symptoms and a
medical history that might have indicated previous lung disease. However, asymptomatic underlying
chronic lung disease cannot be completely excluded. In addition, initial interstitial lung abnormalities or
involvement of the airways in COVID-19 infection cannot be assessed due to the lack of previous chest CT
scan in most cases. However, our findings combined with previous studies support the hypothesis that
severe COVID-19 causes a medium-term decrease in DLCO, limitations in gas exchange and a spectrum of
radiological features not previously reported, pointing towards a considerable small-airway component.
In conclusion, with the analysis of pulmonary function, physical performance, oxygenation and
radiological findings 4 months after COVID-19, our study adds to the growing body of evidence on
post-COVID-19 trajectories. We identified DLCO % predicted at 4 months as the single most important
factor associated with severe/critical respiratory COVID-19, which translates to reduced walking distance
and oxygen desaturation on exercise. The peculiar radiological presentation should be further investigated
to provide an overall assessment of the disease in conjunction with other functional parameters. These
results emphasise the importance of a systematic follow-up after severe and critical COVID-19, with
appropriate management of pulmonary sequelae.
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